Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

AbbVie Inc

Healthcare US ABBV

223.07USD
-4.16(1.83%)

Last update at 2026-06-08T20:02:00Z

Day Range

221.16228.58
LowHigh

52 Week Range

170.55239.13
LowHigh

Fundamentals

  • Previous Close 227.23
  • Market Cap360314.60M
  • Volume4841176
  • P/E Ratio86.32
  • Dividend Yield3.19%
  • EBITDA29254.00M
  • Revenue TTM61160.00M
  • Revenue Per Share TTM34.57
  • Gross Profit TTM 43803.00M
  • Diluted EPS TTM2.36

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 6597.00M 3716.00M 6250.00M 13477.00M 12989.00M
Minority interest -7.00000M -8.00000M -10.00000M -9.00000M -7.00000M
Net income 4226.00M 4278.00M 4863.00M 11836.00M 11542.00M
Selling general administrative 14010.00M 11089.00M 10704.00M 15260.00M 12349.00M
Selling and marketing expenses - 2100.00M 2200.00M - -
Gross profit 42956.00M 39430.00M 33903.00M 40640.00M 38751.00M
Reconciled depreciation 8139.00M 8386.00M 8698.00M 8467.00M 8521.00M
Ebit 9490.00M 6524.00M 8474.00M 18117.00M 17924.00M
Ebitda 17629.00M 14910.00M 17172.00M 26584.00M 26445.00M
Depreciation and amortization 8139.00M 8386.00M 8698.00M 8467.00M 8521.00M
Non operating income net other - - - -2596.00000M -2551.00000M
Operating income 20091.00M 9137.00M 12757.00M 18117.00M 17924.00M
Other operating expenses 41069.00M 47197.00M 41561.00M 39240.00M 37311.00M
Interest expense 2893.00M 2808.00M 2224.00M 2230.00M 2384.00M
Tax provision 2364.00M -570.00000M 1377.00M 1632.00M 1440.00M
Interest income 266.00M 648.00M 540.00M 186.00M 39.00M
Net interest income -2627.00000M -2160.00000M -1684.00000M -2044.00000M -2384.00000M
Extraordinary items - - - - -
Non recurring - - - 697.00M 962.00M
Other items - - - - -
Income tax expense 2364.00M -570.00000M 1377.00M 1632.00M 1440.00M
Total revenue 61160.00M 56334.00M 54318.00M 58054.00M 56197.00M
Total operating expenses 22865.00M 30293.00M 21146.00M 21826.00M 19865.00M
Cost of revenue 18204.00M 16904.00M 20415.00M 17414.00M 17446.00M
Total other income expense net -13494.00000M -5421.00000M -6507.00000M -3293.00000M -3513.00000M
Discontinued operations - - - - -
Net income from continuing ops 4233.00M 4286.00M 4873.00M 11845.00M 11549.00M
Net income applicable to common shares - - - 11836.00M 11542.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 133960.00M 135161.00M 134711.00M 138805.00M 146529.00M
Intangible assets 52641.00M 60068.00M 55610.00M 67439.00M 75951.00M
Earning assets - - - - -
Other current assets 6265.00M 4927.00M 4932.00M 4401.00M 4993.00M
Total liab 137188.00M 131797.00M 124314.00M 121518.00M 131093.00M
Total stockholder equity -3270.00000M 3325.00M 10360.00M 17254.00M 15408.00M
Deferred long term liab - - - 2190.00M 3009.00M
Other current liab 30948.00M 29000.00M 26962.00M 22468.00M 19817.00M
Common stock 18.00M 18.00M 18.00M 18.00M 18.00M
Capital stock 18.00M 18.00M 18.00M 18.00M 18.00M
Retained earnings -15493.00000M -7900.00000M -1000.00000M 4784.00M 3127.00M
Other liab - - - 31716.00M 30982.00M
Good will 35640.00M 34956.00M 32293.00M 32156.00M 32379.00M
Other assets 228.00M - - 4834.00M 4081.00M
Cash 5229.00M 5524.00M 12814.00M 9201.00M 9746.00M
Cash and equivalents - - - - -
Total current liabilities 43289.00M 38749.00M 37841.00M 29538.00M 35194.00M
Current deferred revenue - - -3688.00000M - -
Net debt 63839.00M 62317.00M 46571.00M 54070.00M 66938.00M
Short term debt 8749.00M 6804.00M 7191.00M 4136.00M 12495.00M
Short long term debt 8555.00M 6804.00M 7191.00M 4136.00M 12495.00M
Short long term debt total 69068.00M 67841.00M 59385.00M 63271.00M 76684.00M
Other stockholder equity 13349.00M 13132.00M 13647.00M 14651.00M 15162.00M
Property plant equipment - - - 4935.00M 5110.00M
Total current assets 29062.00M 25582.00M 33002.00M 28463.00M 27928.00M
Long term investments 268.00M 279.00M 304.00M 241.00M 277.00M
Net tangible assets - - - -82341.00000M -96202.00000M
Short term investments 28.00M 31.00M 2.00M 28.00M 84.00M
Net receivables 12589.00M 10919.00M 11155.00M 11254.00M 9977.00M
Long term debt 58941.00M 60340.00M 52194.00M 59135.00M 64189.00M
Inventory 4951.00M 4181.00M 4099.00M 3579.00M 3128.00M
Accounts payable 3592.00M 2945.00M 3688.00M 2934.00M 2882.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - 37.00M 33.00M 28.00M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1144.00000M -1925.00000M -2305.00000M -2199.00000M -2899.00000M
Additional paid in capital - - 20180.00M - -
Common stock total equity - - - 18.00M 18.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 4784.00M 3127.00M
Treasury stock - - -6533.00000M -4594.00000M -3143.00000M
Accumulated amortization - - - - -
Non currrent assets other 9953.00M 9142.00M 8513.00M 3381.00M 1875.00M
Deferred long term asset charges - - - - -
Non current assets total 104898.00M 109579.00M 101709.00M 110342.00M 118601.00M
Capital lease obligations - - - - -
Long term debt total - - - 59135.00M 64189.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 41.00M -20820.00000M -2009.00000M -447.00000M -1398.00000M
Change to liabilities - - - 2147.00M 338.00M
Total cashflows from investing activities -6643.00000M -20820.00000M -2009.00000M -623.00000M -2344.00000M
Net borrowings -304.00000M 7350.00M -4149.00000M -12433.00000M -8414.00000M
Total cash from financing activities -12724.00000M -5211.00000M -17222.00000M -24803.00000M -19039.00000M
Change to operating activities - - - -264.00000M -197.00000M
Net income 4226.00M 4286.00M 4820.00M 11845.00M 11549.00M
Change in cash -295.00000M -7290.00000M 3613.00M -545.00000M 1297.00M
Begin period cash flow 5524.00M 12814.00M 9201.00M 9746.00M 8449.00M
End period cash flow 5229.00M 5524.00M 12814.00M 9201.00M 9746.00M
Total cash from operating activities 19030.00M 18806.00M 22839.00M 24943.00M 22777.00M
Issuance of capital stock - - - - -
Depreciation 8139.00M 8386.00M 8698.00M 8467.00M 8521.00M
Other cashflows from investing activities -5266.00000M -2835.00000M 13.00M 519.00M -159.00000M
Dividends paid 11657.00M 11025.00M 10539.00M -10043.00000M -9261.00000M
Change to inventory -234.00000M -319.00000M -417.00000M -686.00000M -142.00000M
Change to account receivables -1490.00000M 207.00M 66.00M -1455.00000M -1321.00000M
Sale purchase of stock -980.00000M -1708.00000M -1972.00000M -1487.00000M -934.00000M
Other cashflows from financing activities 68.00M 172.00M -562.00000M 1160.00M -674.00000M
Change to netincome - - - 2646.00M 4029.00M
Capital expenditures 1214.00M 974.00M 777.00M 695.00M 787.00M
Change receivables - - - -1455.00000M -1321.00000M
Cash flows other operating - - - 1979.00M -197.00000M
Exchange rate changes - - - - -97.00000M
Cash and cash equivalents changes - - - -483.00000M 1297.00M
Change in working capital -2362.00000M -2782.00000M 2813.00M -258.00000M -1322.00000M
Stock based compensation 955.00M 911.00M 747.00M 671.00M 692.00M
Other non cash items 8604.00M 9454.00M 8650.00M 6149.00M 4235.00M
Free cash flow 17816.00M 17832.00M 22062.00M 24248.00M 21990.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ABBV
AbbVie Inc		 -4.16 1.83% 223.07 86.32 14.33 5.89 50.46 7.04 24.44
LLY
Eli Lilly and Company		 17.73 1.57% 1149.15 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 -0.61 0.26% 232.16 29.17 14.33 3.74 5.18 3.80 15.22
AZN
AstraZeneca PLC		 -4.4 2.37% 181.55 30.69 19.23 5.30 6.45 5.72 17.23
MRK
Merck & Company Inc		 -1.27 1.05% 119.52 59.83 12.33 4.50 6.47 4.94 23.79

Reports Covered

Stock Research & News

View All

Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc

1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Key Executives

Name Title Year Born
Mr. Richard A. Gonzalez Chairman & CEO 1954
Mr. Robert A. Michael Vice Chairman & Pres 1970
Ms. Laura J. Schumacher Vice Chairman of External Affairs & Chief Legal Officer 1963
Mr. Jeffrey Ryan Stewart Exec. VP & Chief Commercial Officer 1969
Mr. Scott T. Reents Exec. VP & CFO 1967
Dr. Azita Saleki-Gerhardt Ph.D. Exec. VP of Operations 1963
Dr. Thomas J. Hudson Sr. VP of R&D and Chief Scientific Officer 1962
Ms. Elizabeth Shea VP of Investor Relations NA
Mr. Perry C. Siatis Exec. VP, Gen. Counsel & Sec. NA
Mr. Timothy J. Richmond Exec. VP & Chief HR Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions